Clinical values of detecting excision repair cross complementing 1 and top-isomerase I in individualized therapies of metastatic colorectal cancer

• Published in: Zhong hua yi xue za zhi Vol. 93; no. 48; p. 3852
• Main Authors: Qiu, Ji-gang, Shen, Da-ming, Huang, Chun-jin, Tang, Jian-xiong
• Format: Journal Article
• Language: Chinese
• Published: China 24.12.2013
• Subjects: Adult; Aged; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; DNA Topoisomerases, Type I - genetics; DNA-Binding Proteins - genetics; Endonucleases - genetics; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pathology, Molecular; Prognosis
• ISSN: 0376-2491

To explore the clinical values of detecting drug related molecules excision repair cross complementing 1 (ERCC1) and top-isomerase I (TOPO I) in individualized therapies of metastatic colorectal cancer. From June 2009 to December 2011, 90 patients at Huadong Hospital with metastatic colorectal cancer were randomly separated into 2 groups after operation. Each group had 45 patients without difference in gender, age or TNM stage. The expressions of ERCC1 and TOPO Iin cancer tissues were detected by immunohistochemical staining. The testing group received individualized chemotherapies following the expression results while the control group had random chemotherapies. The survival difference between two groups was analyzed by log-rank test and Kaplan-Meier analysis. And curative effect was analyzed by χ(2) or Fisher's analysis. The expressions of ERCC1 and TOPO I had no statistical significance between two groups (both P > 0.05). In the testing group, the median survival time was 281 days and the beneficial ratio